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Ketogenic diet enhances 
neurovascular function with altered 
gut microbiome in young healthy 
mice
David Ma1, Amy C. Wang1, Ishita Parikh1, Stefan J. Green  2, Jared D. Hoffman1,3,  
George Chlipala2, M. Paul Murphy1,4, Brent S. Sokola5, Björn Bauer5, Anika M. S. Hartz1,3 &  
Ai-Ling Lin1,3,6
Neurovascular integrity, including cerebral blood flow (CBF) and blood-brain barrier (BBB) function, 
plays a major role in determining cognitive capability. Recent studies suggest that neurovascular 
integrity could be regulated by the gut microbiome. The purpose of the study was to identify if 
ketogenic diet (KD) intervention would alter gut microbiome and enhance neurovascular functions, 
and thus reduce risk for neurodegeneration in young healthy mice (12–14 weeks old). Here we show 
that with 16 weeks of KD, mice had significant increases in CBF and P-glycoprotein transports on BBB 
to facilitate clearance of amyloid-beta, a hallmark of Alzheimer’s disease (AD). These neurovascular 
enhancements were associated with reduced mechanistic target of rapamycin (mTOR) and increased 
endothelial nitric oxide synthase (eNOS) protein expressions. KD also increased the relative abundance 
of putatively beneficial gut microbiota (Akkermansia muciniphila and Lactobacillus), and reduced that 
of putatively pro-inflammatory taxa (Desulfovibrio and Turicibacter). We also observed that KD reduced 
blood glucose levels and body weight, and increased blood ketone levels, which might be associated 
with gut microbiome alteration. Our findings suggest that KD intervention started in the early stage 
may enhance brain vascular function, increase beneficial gut microbiota, improve metabolic profile, and 
reduce risk for AD.
Neurovascular functions play a critical role in determining cognitive capability and mental health1. Studies have 
shown that neurovascular risk is highly associated with accelerated decline in language ability, verbal memory, 
attention and visuospatial abilities2,3. Specifically, reduced cerebral blood flow (CBF) is linked to increased risk 
for anxiety, depression, and dementia3–5, while impaired blood-brain-barrier (BBB) function is associated with 
neuroinflammation, synaptic dysfunction, and psychiatric disorders6,7.
Emerging evidence suggests that gut microbiota play an important role in determining brain vascular integ-
rity. Braniste et al. recently showed that BBB permeability is increased in germ-free mice due to lack of butyrate, 
a short chain fatty acid (SCFA) produced by microorganisms such as Clostridium tyrobutyricum8. Similarly, 
Akkermansia muciniphila can produce SCFAs such as acetate and propionate9, and the lack of A. muciniphila can 
alter the microbial ecology of the mucus layer10 and lead to damage of tight junctions of BBB and the gut7,11. BBB 
dysfunction further leads to reduced CBF and impaired clearance of amyloid-beta (Aβ) plaques, a hallmark of 
Alzheimer’s disease (AD)1,6. Interventions that maintain gut microbiome and neurovascular integrity may be thus 
crucial for impeding neurological disorders.
Ketogenic diet (KD), a high fat and low carbohydrate diet, has been an effective therapeutic for a wide range 
of neurological disorders12. Clinically, KD has been used to treat epilepsy12,13, Parkinson’s disease14, and autism15. 
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Furthermore, significant evidence for KD as a therapeutic for a broader range of conditions can be found in 
preclinical studies where KD has been shown to protect brain function in Alzheimer’s disease16, traumatic brain 
injury17, and ischemic stroke18. A recent study showed that KD significantly increased regional CBF in a mouse 
model with ischemic stroke19. In another study with an autism mouse model, KD mitigated neurological symp-
toms potentially through changes in the gut microbiome20. Collectively, KD may be protective against various 
neurological disorders, possibly through the restoration of neurovascular function and by maintaining healthy 
gut microbiome.
While KD has beneficial effects in disease systems, it is unclear if similar impacts persist in healthy conditions. 
Therefore, the goal of the study was to identify whether administration of KD to young healthy mice would also 
benefit their neurovascular functions and gut microbiome composition, and whether these changes could con-
tribute to lowering risk for AD, the most common form of dementia. We were also interested in identifying poten-
tial signaling pathways in association with vascular changes induced by KD. We hypothesized that KD would 
increase neuroprotection for young healthy mice, and reduce their risk for neurodegeneration, by enhancing their 
neurovascular functions and increasing the abundance of beneficial gut microbiota.
Results
Ketogenic diet enhances neurovascular functions. We used magnetic resonance imaging (MRI) to 
measure CBF and confocal microscopy to determine BBB function. Figure 1a shows representative CBF maps 
superimposed on structural brain images. The color code indicates the level of CBF in a linear scale. We found 
that KD-fed mice had significantly elevated CBF globally and regionally, particularly in ventromedial hypo-
thalamus (VMH) (11.82%; p < 0.0001; Fig. 1b). We previously reported that inhibiting mechanistic target of 
rapamycin (mTOR) signaling increases neurovascular function by activating endothelial nitric oxide synthase 
(eNOS)21,22. In this study, we also found that mTOR protein expression was reduced (−29.9%; p < 0.01) while 
Figure 1. Ketogenic diet enhances neurovascular functions. (a) Representative cerebral blood flow (CBF) 
maps superimposed on structural images; color code indicates level of CBF in a linear scale. KD mice 
exhibited significantly higher CBF in the (b) ventromedial hypothalamus. Data are presented as mean ± SEM, 
***p < 0.001. (c) Western blot (WB) images for mTOR, P-gp, and eNOS from the cortical vasculature, β-Actin 
was used as loading control. (d) The corresponding values of the levels of protein expression. WB data from KD 
mice were normalized to β-Actin and compared to the control mice (100%), *p < 0.05, **p < 0.01, ***p < 0.001. 
(e) Representative confocal images showing increased luminal accumulation of NBD-CSA fluorescence in 
brain capillaries isolated from KD mice compared to control mice, indicating higher P-gp transport activity. 
Corresponding quantitative fluorescence data; images are shown in arbitrary fluorescence units (scale 0–255). 
Data are mean ± SEM for 10 capillaries from one preparation of 10 mice per group, ***p < 0.001. mTOR: 
mechanistic target of Rapamycin; P-gp: P-glycoprotein; eNOS; endothelial nitric oxide synthase.
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eNOS levels were increased (111.5%; p < 0.001) in mice fed with KD, compared to control mice (Fig. 1c). In addi-
tion, protein expression levels of P-glycoprotein (P-gp), which transports Aβ across at the BBB, were also signifi-
cantly elevated in KD-fed mice (50.5%; p < 0.001). The Western blots are shown in Fig. 1c and the corresponding 
values are shown in Fig. 1d. We further used confocal microscope imaging to assess P-gp transport activity23. This 
assay measures accumulation of [N-ε(4-nitro-benzofurazan-7-yl)-DLys(8)]-cyclosporin A (NBD-CSA), a fluo-
rescent P-gp substrate in the capillary lumen. Figure 1e (top) shows representative confocal images of capillaries 
incubated to steady state in a medium containing 2 µM NBD-CSA; the intensity of fluorescence in the capillary 
lumen reflects the amount of NBD-CSA transported by P-gp. The corresponding quantitative results are shown 
in Fig. 1e (bottom) – KD mice had significantly enhanced P-gp transport activity (185.38%; p < 0.001) in capil-
laries compared to capillaries isolated from control mice. Taken together, these results indicate that KD enhanced 
neurovascular function and increased Aβ clearance.
Ketogenic diet alters gut microbial diversity and increases beneficial microbiota. Figure 2a 
shows Shannon index (H) for alpha diversity, which is measure of within-sample diversity and is a synthesis of 
both the richness and evenness of the microbial community in a particular sample. Shannon indices calculated 
based on rarefied datasets (10,000 sequences/sample) were significantly different between control and KD mice 
(Mann-Whitney U test; p = 0.018), with the fecal microbiomes of KD mice having lower diversity. Figure 2b 
shows a genus-level metric multi-dimensional scaling (mMDS) plot of 16s rRNA gene amplicon microbiome 
data generated from a Bray-Curtis resemblance matrix. The fecal microbiomes of control and KD mice were sig-
nificantly different as assessed by analysis of similarity (ANOSIM; R = 0.473, p = 0.0002). These results indicate 
Figure 2. Ketogenic diet alters gut microbial diversity and increases pro-vascular microbiota. (a) Microbial 
diversity (Shannon index) was significantly higher in fecal samples from control relative to KD mice (Mann-
Whitney U < 0.02). (b) Genus-level metric multi-dimensional scaling (mMDS) plot of 16S rRNA gene amplicon 
microbiome data was generated with a Bray-Curtis resemblance matrix. Fecal microbial communities of control 
and KD mice were significantly different in terms of individual taxa (ANOSIM R = 0.473; p = 0.0002), as 
described in the text and Table 1. All samples were standardized and square root transformed. 2D stress = 0.16.
Genera with significantly different relative abundance between control and KD animals* Control KD p-value FDRC
Phylum Actinobacteria
Class Coriobacteriia; Order Coriobacteriales; Family Coriobacteriaceae; Genus Adlercreutzia 28.5 60.2 0.002 0.019
Phylum Firmicutes
Class Bacilli; Order Lactobacillales; Family Lactobacillaceae; Genus Lactobacillus 142.8 453.4 0.006 0.008
Class Bacilli; Order Turicibacterales; Family Turicibacteraceae; Genus Turicibacter 120.2 1.6 0.000 0.008
Class Clostridia; Order Clostridiales; Family Clostridiaceae; Genus Clostridium 2.1 0.2 0.002 0.019
Class Clostridia; Order Clostridiales; Family Lachnospiraceae; Genus Dorea 19.7 4.0 0.002 0.019
Class Erysipelotrichi; Order Erysipelotrichales; Family Erysipelotrichaceae; Genus Clostridium 187.0 831.2 0.003 0.020
Phylum Proteobacteria
Class Deltaproteobacteria; Order Desulfovibrionales; Family Desulfovibrionaceae; Genus Desulfovibrio 53.4 0.0 0.001 0.015
Phylum Verrucomicrobia
Class Verrucomicrobiae; Order Verrucomicrobiales; Family Verrucomicrobiaceae; Genus Akkermansia** 792.1 1943.9 0.005 0.028
Table 1. Diet changes in gut microbiome composition. *Data for ‘Control’ and ‘KD’ are presented as mean 
number of reads per sample, based on a rarefied sequencing depth of 10,000 sequences/sample. The p-value 
is derived from a Kruskal-Wallis test, and the FDRC is the Benjamini-Hochberg false-discovery rate adjusted 
p-value. Only those genus-level taxa with an FDRC <0.05 are shown. **All Akkermansia sequences were 
annotated to the taxonomic level of species as A. muciniphila.
www.nature.com/scientificreports/
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that KD significantly altered fecal microbial composition, and the effects included both a significant decrease in 
microbial diversity and a significant shift in microbial community composition.
We used a group significance test (Kruskal-Wallis test)24 to identify specific microbial taxa, which differed in 
relative abundance between fecal samples of KD and control mice. Table 1 shows the genera and species that were 
significantly different between control and KD mice (Kruskal-Wallis test, with Benjamini-Hochberg false discov-
ery rate p < 0.05). We found that KD mice had significant increases in the relative abundance of A. muciniphila 
and Lactobacillus (approximately 2.5 and 3.2-fold increases, respectively). Both taxa have members that are capa-
ble of producing SCFAs25,26 and members of the genus Lactobacillus have been used elsewhere as probiotics27. Two 
low abundance genera of putative acetate producers (<0.3% relative abundance) within the order Clostridiales, 
Clostridium and Dorea28, were significantly lower in KD mice. The relative abundance of bacteria from the gen-
era Desulfovibrio and Turicibacter was significantly and substantially lower in KD mice. Desulfovibrio sequences 
were not detected in KD mice but present at an average relative abundance of 0.53% in control animals, while 
Turicibacter relative abundance was nearly two orders of magnitude higher in the fecal samples of control mice 
relative to KD mice. Desulfovibrio are sulfate-reducing bacteria associated with inflammatory bowel disease29, 
while members of the genus Turicibacter were shown to increase with diet-induced obesity30. Collectively, KD 
increased the relative abundance of microbiota that are putatively able to protect neurovascular integrity, as well 
as reduced those which may induce inflammation.
Ketogenic diet modulates blood ketone and glucose, and decreases body weight. A. mucin-
iphila can increase insulin sensitivity31, and exhibits a negative correlation with body-mass index32. Consistent 
with our gut microbiome findings, we observed a significant decrease in blood glucose level in the KD mice 
(Fig. 3a; −19.97%; p = 0.01). With KD feeding, mice exhibited significantly higher ketone concentration when 
compared to the control group (Fig. 3b; 43.48%; p = 0.0004). Interestingly, there was a significant inverse corre-
lation between ketone level and blood glucose measurements (Fig. 3c; Pearson’s r = − 0.58; r2 = 0.33, p < 0.01). 
Another interesting aspect of the present study is that KD mice lost body weight despite having higher energy 
intake (7.24 kcal/gm) compared to the control mice (3.79 kcal/gm). KD mice exhibited reduced body weight by 
week 3 (Fig. 3d; −15.50%; p = 0.0096), and this trend continued for the remainder of the study. At the time of 
the final measurement, the KD mice maintained significantly lower weights than the control mice (−14.58%; 
p = 0.0042). Our findings are consistent with literature that KD reduces blood glucose levels33 and body weight34.
Discussion
In the present study, we demonstrated that KD enhanced neurovascular functions and increased beneficial gut 
microbiota in young healthy mice. In particular, KD enhanced BBB function by increasing protein expression and 
transport activity of the Aβ transporter P-gp, increased CBF in VMH, and reduced mTOR with increased eNOS 
protein expressions. In addition, KD increased potentially beneficial gut microorganisms, including A. mucin-
iphila and bacteria from the genus Lactobacillus. KD also reduced potentially pro-inflammatory taxa, including 
bacteria from the genera Desulfovibrio and Turicibacter. We also found that mice fed with KD had reduced blood 
glucose levels and body weight, and increased blood ketone body levels; there was an inverse correlation between 
blood glucose and ketone bodies levels. Collectively, KD showed multifactorial benefits for mice even under 
healthy conditions.
The enhancements of CBF, BBB transporter activities, and potentially increased Aβ clearance suggest that 
mice with KD may have lower risk to develop age-related neurodegenerative disorders, including AD. This is con-
sistent with literature that KD reduces Aβ toxicity and restores memory in animal models that develop AD-like 
symptoms35–38. This also agrees with our previous findings showing that preserving CBF and BBB integrity is crit-
ical in preventing AD development in a mouse model with human APOE4 gene, the strongest genetic risk factor 
for AD39; and restoring CBF improves memory in a symptomatic AD mouse model21. Our findings are consistent 
with literature showing that an acute increase in ketone body levels elevated CBF in rats37 and humans36.
We further demonstrate that mTOR inhibition may play an important role in neurovascular enhancements. 
mTOR is a nutrient sensor and its activity can be down-regulated when glucose availability is reduced or ketogen-
esis is increased40. Similar to caloric restriction, mTOR inhibition can preserve brain metabolism with age41, 
potentially due to the shift from glucose to ketone body utilization42. In the present study, we found that KD 
mice exhibited significantly lower expression of mTOR, but significantly increased expression of eNOS. This is 
consistent with our previous study using rapamycin, showing that mTOR inhibition can activate eNOS, which 
causes the release of nitric oxide, a vessel dilator, and consequently elevates CBF21,23. This is also consistent with 
studies showing that down-regulation of mTOR is associated with elevated P-gp expression23. The neurovascular 
enhancements by mTOR inhibition were associated with preserved white matter integrity and long-term mem-
ory, and reduced anxiety in aging mice23,43.
Gut microbiome alterations induced by KD may also contribute to the neurovascular enhancements. We 
found that KD significantly increased the relative abundance of A. muciniphila and Lactobacillus, known to 
produce SCFAs25–27. SCFAs are transported by monocarboxylate transporters expressed at the BBB44,45. Lack of 
SCFAs can cause higher BBB permeability7,8,11. On the other hand, we found that Desulfovibrio was absent in KD 
mice. This is consistent with a prior study showing that KD significantly decreases the abundance of Desulfovibrio 
in Glucose Transporter 1 Deficiency Syndrome29. Members of the genus Desulfovibrio are capable of respiring sul-
fate and producing hydrogen sulfide, which is known to induce gut barrier impairment46. Consequently, reducing 
the abundance of Desulfovibrio may also facilitate BBB and neurovascular enhancements. Together, changes in 
relative abundance of A. muciniphila, Lactobacillus, and Desulfovibrio may contribute to protection of neurovas-
cular functions.
We found that KD decreased overall microbial diversity. This is likely a result of reduced carbohydrate intake, 
which decreases the polysaccharide content that many gut bacteria derive energy from47. Although other studies 
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suggested that reduced microbiome diversity may be associated with disease progression48, we found that levels 
of several beneficial microbiota were increased, even though the overall diversity was reduced by KD. In part, 
the decrease in diversity (Shannon index) can be attributed to the substantially higher relative abundance of A. 
muciniphila in KD mice, reaching nearly 20% of the observed microbial community. Future studies are needed to 
further identify the different contributions between overall diversity and underlying taxonomy for health and dis-
eases. In addition, shotgun metagenome and metatranscriptome sequencing efforts will be required to associate 
specific metabolic capabilities (e.g., SCFAs production) with identified taxa, and to demonstrate where and when 
these genes are expressed in situ in the gastrointestinal tract.
We confirmed that KD is able to reduce body weight34 and lower blood glucose level33. This could be due to 
increased relative abundance of A. muciniphila and Lactobacillus spp. The relative abundance of A. muciniphila 
also increases when type 2 diabetic patients are given metformin49, a prescribed medication to increase glucose 
utilization and reduce body weight by activating AMP-activated protein kinase (AMPK) pathway50. Accordingly, 
A. muciniphila is associated with increased insulin sensitivity31 and reduced body weight32. Similar results could 
be elicited by Lactobacillus through SCFAs production. In line with this, Lactobacillus has been shown in several 
studies to decrease body weight and fat51.
Being able to maintain proper body weight and blood glucose level is crucial for reducing risk for AD, which 
is known as type 3 diabetes with increased glucose intolerance in the brain52. In fact, diabetes or obesity is highly 
associated with glucose intolerance, insulin insensitivity, and increased risk for AD53. Recent advances indicate 
that excessive white fat increases secretion of pro-inflammatory cytokines from adipocytes, which could conse-
quently lead to neuroinflammation, Aβ retention, brain cell death, and dementia54. In a study with obese rats, 
KD reduced their body weight and improved their lipid profile55. In addition, KD decreases pro-inflammatory 
cytokines (e.g., TNF-α), down-regulates brain amyloid protein precursor, and improves brain oxidative stress of 
the obese rats. Furthermore, KD improves hippocampal glycolytic and tricarboxylic acid cycle intermediates and 
amino acid in a 3xTgAD mouse model56, suggesting that KD may also improve insulin sensitivity in the brain57. It 
indicates that KD-induced body weight loss may evoke metabolic and immune function changes that potentially 
lead to neuroprotective effects. This is consistent with a human study that diet-induced weight loss improves 
functional brain responses during an episodic memory task58.
Although KD mice had higher energy intake per gram of the food (due to high fat content) compared to the 
control mice, they still showed lower body weight. As ketone bodies could enhance fatty acid metabolism, we 
speculate that KD would switch from burning carbohydrate to fat and thus facilitate fat utilization more effec-
tively in the body59. This is consistent with a clinical study that people with obesity lost three times more visceral 
adipose tissue with KD60.
Figure 3. Ketogenic diet modulates blood ketone and glucose, and decreases body weight. (a) KD mice had 
significantly lower blood glucose and (b) significantly higher blood ketone levels than control mice. (c) A scatter 
plot of blood ketone and glucose showing an inverse linear relationship (Pearson’s r = −0.5761, p < 0.01) where 
each point represents a mouse (n = 19). (d) KD mice had a significant decrease in weight over the 16 weeks 
compared to control mice.
www.nature.com/scientificreports/
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There were several limitations in the present study. We did not measure levels of SCFAs, and tight junction 
protein in the intestinal barrier and BBB. Therefore, we could not identify further linkages between the gut 
microbiome changes and brain vascular protection. In addition, we used DNA-based amplicon profiling of the 
microbial community in fecal samples to determine the diversity and taxonomy of gut microbiota. We acknowl-
edge that the various compartments of the gastrointestinal (GI) tract harbor different bacterial populations61; 
therefore, future studies will need to include different parts of the GI tracts for gut microbiome analysis, and to 
incorporate shotgun sequencing approaches to the community profiling to improve taxonomic resolution and to 
measure gene expression activity.
In conclusion, we have demonstrated that KD enhanced neurovascular functions, which might be associated 
with the diet-induced changes in gut microbiome. Our results indicate that KD may not only be beneficial in 
disease states, but also in healthy condition. These findings imply that dietary intervention started in early stages 
may evoke neuroprotective effects via neurovascular and gut microbiome changes. Future studies will be needed 
to further identify the mechanism linking brain and gut interactions for KD-induced neuroprotective effects in 
both healthy and disease states. Understanding nutritional effects on central and enteric nervous systems, and 
their interactions, has profound implications for neuroprotection in humans.
Materials and Methods
Animals and Diet. We used C57BL/6 male mice (12–14 weeks of age) obtained from the National Institutes 
of Health. We determined the sample size with the power that could perform the comparison at a 0.05 level of 
significance, with a 90% chance of detecting a true difference of all the measurements between the two groups; 
N = 9–10 per group were used in the study. After arriving at our facilities, each mouse was given its own cage 
housed in a specific pathogen-free facility to avoid microbiome transfer62. The control regimen (type F1515) 
consisted of 3.79 kcal/gm pellets composed of 65.2% carbohydrates, 18.1% protein, 5.1% fat, 4.8% fiber, 2.9% 
ash, and less than 10% moisture. The KD regimen (type F3666), in the form of a 7.24 kcal/gm paste, consisted of 
75.1% fat (composed of saturated, monounsaturated, and polyunsaturated fatty acids), 8.6% protein, 4.8% fiber, 
3.2% carbohydrates, 3.0% ash, and less than 10% moisture. Both diets were obtained from Bio-Serv. All mice 
were fed ad libitum for 16 weeks, and body weight was measured once a week. The amount of remaining diet was 
weighted each week to determine the food intake of the mice. We did not find a significant difference in food 
intake between the control (46 ± 3 g/mouse/week) and KD mice (47 ± 2 g/mouse/week; p > 0.5). All experimental 
procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of 
Kentucky (UK) and in compliance with the ARRIVE guidelines63.
Cerebral Blood Flow Measurement. We measured CBF using MRI-based arterial spin labeling tech-
niques. Details have been described in a previous study23. Briefly, MRI experiments were performed on a 7T MR 
scanner (Clinscan, Bruker BioSpin, Germany) at the Magnetic Resonance Imaging & Spectroscopy Center of 
the University of Kentucky. Mice were anesthetized with 4.0% isoflurane for induction and then maintained in 
a 1.2% isoflurane and air mixture using a nose cone. Heart rate (90–110 bpm), respiration rate (50–80 breaths/
min), and rectal temperature (37 ± 1 °C) was continuously monitored and maintained. A water bath with cir-
culating water at 45–50 °C was used to maintain the body temperature. A whole-body volume coil was used for 
transmission and a mouse brain surface coil was placed on top of the head for receiving. We measured CBF using 
MRI-based pseudo-continuous arterial spin labeling (pCASL) techniques23. Paired control and label images were 
acquired in an interleaved fashion with a train of Hanning window-shaped radiofrequency pulses of duration/
spacing = 200/200 μs, flip angle = 25° and slice-selective gradient = 9 mT/m, and a labeling duration = 2100 ms. 
The images were acquired by 2D multi-slice spin-echo echo planner imaging with FOV = 18 × 18 mm2, 
matrix = 128 × 128, slice thickness = 1 mm, 10 slices, TR = 4,000 ms, TE = 35 ms, and 120 repetitions. pCASL 
images were analyzed with in-house written codes in MATLAB (MathWorks, Natick, MA) to obtain quantita-
tive CBF (with units of mL/g per minute). Brain structural T2-weighted images were acquired with field of view 
(FOV) = 18 × 18 mm2, matrix = 256 × 256; slice thickness = 1 mm, 10 slices, repetition time (TR) = 1500 ms, and 
echo time (TE) = 35 ms. The CBF images were then superimposed to the corresponding structural images using 
Multi-Image Analysis GUI (Mango) software (http://rii.uthscsa.edu/mango/).
Gut Microbiome Analyses. Fecal DNA Amplification. The experimental protocol has been described in 
a previous study64. Fecal samples were collected from control and KD mice and frozen at −80 °C until further 
use. The PowerSoil DNA Isolation Kit (MO BIO Laboratories, Inc.) was used for fecal DNA extraction, according 
to the manufacturer’s protocol. Genomic DNA was PCR amplified with primers 515 F modified and 926R65 tar-
geting the V4-V5 regions of microbial 16S rRNA genes using a two-stage “targeted amplicon sequencing (TAS)” 
protocol66. The primers contained 5′ common sequence tags (known as common sequence 1 and 2, CS1 and CS2) 
as described previously67. First stage amplifications were performed with the following thermocycling condi-
tions: 95 °C for 3 mins, 28 cycles of 95 °C for 45 sec, 50 °C for 45 sec, 72 °C for 1:30 minutes and final elongation 
at 72 °C for 10 minutes. The PCR master mix was made in a total volume of 25 µl of reaction mixture containing 
4 µl (100 ng) of DNA template, 0.5 µl (20 µM) of each forward and reverse primers, 12.5 µl of PCR ready-to-use 
mixture (MyTaq HS Mix 2x, Bioline, London, UK) and 7.5 µl of distilled water.
Subsequently, a second PCR amplification was performed in 10 microliter reactions in 96-well plates. A mas-
termix for the entire plate was made using the MyTaq HS 2X mastermix. Each well received a separate primer 
pair with a unique 10-base barcode, obtained from the Access Array Barcode Library for Illumina (Fluidigm, 
South San Francisco, CA; Item# 100-4876). These Access Array primers contained the CS1 and CS2 linkers at 
the 3′ ends of the oligonucleotides. Cycling conditions were as follows: 95 °C for 5 minutes, followed by 8 cycles 
of 95 °C for 30”, 60 °C for 30” and 72 °C for 30”. A final, 7-minute elongation step was performed at 72 °C. PCR 
products were purified using SequalPrep plates (Life Technologies) according to the manufacturer’s instructions. 
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Subsequently, these PCR products were quantified using a Quant-iT PicoGreen dsDNA Assay Kit (Thermo 
Fisher), implemented on a Genios Pro Fluorescence microplate reader (Tecan). PCR products were then pooled 
using PicoGreen quantification results, using an epMotion5075 liquid handling workstation (Eppendorf).
The pooled libraries, with a 15% phiX spike-in, were loaded on to a MiSeq v3 flow cell, and sequenced using 
an Illumina MiSeq sequencer, with paired-end 300 base reads. Fluidigm sequencing primers, targeting the CS1 
and CS2 linker regions, were used to initiate sequencing. De-multiplexing of reads was performed on instru-
ment. Second stage PCR amplification and library pooling was performed at the DNA Services (DNAS) facility, 
Research Resources Center (RRC), University of Illinois at Chicago (UIC). Sequencing was performed at the 
W.M. Keck Center for Comparative and Functional Genomics at the University of Illinois at Urbana-Champaign 
(UIUC).
Microbial Analysis. Forward and reverse reads were merged using PEAR68. Primer sequences were identified 
using Smith-Watermann alignment and trimmed from the sequence. Reads that lacked either primer sequence 
were discarded. Sequences were then trimmed based on quality scores using a modified Mott algorithm with 
PHRED quality threshold of p = 0.01, and sequences shorter than 300 bases after trimming were discarded. 
QIIME v1.8 was used to generate OTU tables and taxonomic summaries24. Briefly, the resulting sequence files 
were merged with sample information. OTU clusters were generated in a de novo manner using the UCLUST 
algorithm with a 97% similarity threshold69. Chimeric sequences were identified using the USEARCH61 algo-
rithm with the GreenGenes 13_8 reference sequences70. Taxonomic annotations for each OTU were using the 
UCLUST algorithm and GreenGenes 13_8 reference with a minimum similarity threshold of 90%69,70. Taxonomic 
and OTU abundance data were merged into a single OTU table and summaries of absolute abundances of taxa 
were generated for all phyla, classes, orders, families, genera, and species present in the dataset. The taxonomic 
summary tables were then rarefied to a depth of 10,000 counts per sample.
Shannon and Bray-Curtis indices were calculated with default parameters in software package Primer771. The 
rarefied species data, taxonomic level 6, were used to calculate both indices. Significant difference among tested 
groups was determined using the Kruskal-Wallis one-way analysis of variance. The group significance tests were 
performed on the rarefied species data using the group_significance.py script within the QIIME v1.8 package. 
The gene amplicon sequence data generated as part of this study have been submitted to the NCBI BioProject 
database (PRJNA401034).
P-glycoprotein (P-gp) Transport Determination and Western Blotting. Capillary isolation. 
Details of the experiments have been described in previous studies23,64. Brain capillaries were isolated from mice 
according to a previously described protocol23. Briefly, mice were euthanized by CO2 inhalation and decapitated; 
brains were immediately harvested and collected in ice-cold DPBS buffer supplemented with 5 mM D-glucose 
and 1 mM Na-pyruvate, pH 7.4. Brains were dissected by removing meninges, choroid plexus and white matter, 
and homogenized in DPBS. The brain homogenate was mixed with Ficoll® and centrifuged at 5,800 g for 15 min 
at 4 °C. The capillary pellet was resuspended in 1% BSA buffer and first passed through a 300 µm nylon mesh 
followed by filtration through a 27 µm nylon mesh. Capillaries retained by the 27 µm nylon mesh were collected 
and washed with DPBS buffer, and used for experiments.
P-glycoprotein transport activity. Isolated brain capillaries were incubated for 1 h at room temperature 
with 2 μM NBD-CSA (custom-synthesized by R. Wenger, Basel, Switzerland) in DPBS buffer. Per treatment 
group, 10 capillary images were acquired by confocal microscopy (Leica TSP SP5 Confocal Microscope with 
Environmental Chamber, 63 × D-Water UV objective, numerical aperture 1.2, 488-nm line of an argon laser, 
Leica Microsystems). Confocal images were analyzed by quantitating luminal NBD-CSA fluorescence with Image 
J software (v.1.45 s; Wayne Rasband, NIH). Specific, luminal NBD-CSA fluorescence was taken as the differ-
ence between total luminal fluorescence and fluorescence in the presence of the P-glycoprotein specific inhibitor 
PSC833 (5 μM, Novartis, Basel, Switzerland).
Western blotting and quantification. To determine protein expression, isolated brain capillaries were homogenized 
in tissue lysis buffer containing protease inhibitor cocktail. Homogenized brain capillary samples were centrifuged 
at 10,000 g for 15 min at 4 °C, followed by centrifugation of the denucleated supernatants at 100,000 g for 90 min at 
4 °C. Pellets (crude brain capillary plasma membranes) were resuspended and protein concentrations were deter-
mined using the Bradford protein assay. Western blots were performed using the NuPage™ electrophoresis and 
blotting system from Invitrogen (Carlsbad, CA, USA). Blotting membranes were incubated overnight with antibody 
to P-gp (C219; MA1-26528, ThermoFisher, 1 μg/ml), mTOR (ab134903, Abcam, 1 μg/ml), GLUT1 (ab652, Abcam, 
1 μg/ml), and β-actin (ab8226 from Abcam, 1:1000, 1 μg/ml). Proteins were detected using SuperSignal® West Pico 
Chemoluminescent substrate (Pierce, Rockford, IL, USA) and protein bands were visualized with a BioRad Gel 
Doc™ XRS imaging system. Image Lab 5.0 software from Bio-Rad Laboratories was used for densitometric anal-
yses of band intensities and digital molecular weight analyses; the molecular weight marker was RPN800E (GE 
Healthcare, Chalfont St. Giles, Buckinghamshire, UK). Linear adjustments of contrast and brightness were applied 
to entire Western blot images. None of the Western blots shown were modified by nonlinear adjustments.
Blood Glucose and Ketone Bodies Measurements. The procedure has been described in a previous study43. 
When the mice were sacrificed, blood samples were collected in 500 μl lithium heparin 12.5 IU Terumo Capiject 
Capillary blood collection tubes (Vacutainer K2 EDTA) to avoid blood coagulation. A total of 1–2 μl of blood 
sample were used to measure blood glucose level using a blood glucose meter and a test strip (Clarity Plus, Boca 
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Raton, FL, USA). Another 10 μl of blood sample was used for ketone bodies level measurement using a STAT-Site 
M (β-Hydroxybutyrate) meter and a test strip (Standbio Ketosite STAT-Site M-β HB, Boerne, TX, USA).
Statistics. Statistical analyses were performed using GraphPad Prism 7 (GraphPad, San Diego, CA, USA). 
One-tailed Student’s t-test was performed for determination of differences between the two groups. Values of 
p < 0.05 were considered statistically significant.
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